Michael B Atkins

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi request reprint Angiopoietin 2 is a potential mediator of high-dose interleukin 2-induced vascular leak
    Diana C Gallagher
    Division of Pulmonary and Critical Care, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Clin Cancer Res 13:2115-20. 2007
  2. pmc Management of metastatic renal cell carcinoma in patients with poor prognosis
    Andrea Bullock
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Boston, MA, USA
    Cancer Manag Res 2:123-32. 2010
  3. pmc Defining the critical hurdles in cancer immunotherapy
    Bernard A Fox
    Earle A, Chiles Research Institute, Robert W, Franz Research Center, Providence Cancer Center, Providence Portland Medical Center, Portland, OR, USA
    J Transl Med 9:214. 2011
  4. pmc Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma
    Antoni Ribas
    University of California, 11 934 Factor Building, UCLA Medical Center, Los Angeles, CA 90095 1782, USA
    J Transl Med 7:68. 2009
  5. pmc Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trial
    Helen Gogas
    First Department of Medicine, University of Athens, Medical School, Athens, Greece
    J Transl Med 8:108. 2010
  6. ncbi request reprint Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer
    Michael Atkins
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Boston, MA, USA
    Clin Cancer Res 11:3714-21. 2005
  7. ncbi request reprint Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy
    Melissa P Upton
    Beth Israel Deaconess Medical Center, Department of Pathology, Boston, MA 02215, USA
    J Immunother 28:488-95. 2005
  8. ncbi request reprint Innovations and challenges in melanoma: summary statement from the first Cambridge conference
    Michael B Atkins
    Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Clin Cancer Res 12:2291s-2296s. 2006
  9. ncbi request reprint Cytokine-based therapy and biochemotherapy for advanced melanoma
    Michael B Atkins
    Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA
    Clin Cancer Res 12:2353s-2358s. 2006
  10. doi request reprint Treatment selection for patients with metastatic renal cell carcinoma: identification of features favoring upfront IL-2-based immunotherapy
    Michael B Atkins
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center, MASCO Bldg, Rm 412, 375 Longwood Ave, Boston, MA 02215, USA
    Med Oncol 26:18-22. 2009

Collaborators

Detail Information

Publications93

  1. ncbi request reprint Angiopoietin 2 is a potential mediator of high-dose interleukin 2-induced vascular leak
    Diana C Gallagher
    Division of Pulmonary and Critical Care, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Clin Cancer Res 13:2115-20. 2007
    ..However, a major toxicity is vascular leak syndrome (VLS). We previously reported elevated serum angiopoietin 2 (Ang2) in septic patients with vascular leak and hypothesized that Ang2 might also contribute to HDIL2 VLS...
  2. pmc Management of metastatic renal cell carcinoma in patients with poor prognosis
    Andrea Bullock
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Boston, MA, USA
    Cancer Manag Res 2:123-32. 2010
    ..Ongoing translational research efforts may help to define novel treatment approaches specific for patients with metastatic RCC and poor prognostic features...
  3. pmc Defining the critical hurdles in cancer immunotherapy
    Bernard A Fox
    Earle A, Chiles Research Institute, Robert W, Franz Research Center, Providence Cancer Center, Providence Portland Medical Center, Portland, OR, USA
    J Transl Med 9:214. 2011
    ..Each of these hurdles can significantly delay clinical translation of promising advances in immunotherapy yet if overcome, have the potential to improve outcomes of patients with cancer...
  4. pmc Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma
    Antoni Ribas
    University of California, 11 934 Factor Building, UCLA Medical Center, Los Angeles, CA 90095 1782, USA
    J Transl Med 7:68. 2009
    ..18-IL2), a humanized anti-GD2 monoclonal antibody fused to interleukin-2 (IL2), in patients with unresectable, stage IV cutaneous melanoma as measured by induction of immune activation at the tumor site and in peripheral blood...
  5. pmc Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trial
    Helen Gogas
    First Department of Medicine, University of Athens, Medical School, Athens, Greece
    J Transl Med 8:108. 2010
    ..Specific CTLA-4 polymorphisms have previously shown an association with response to CTLA-4 blockade in patients with metastatic melanoma and the development of autoimmunity...
  6. ncbi request reprint Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer
    Michael Atkins
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Boston, MA, USA
    Clin Cancer Res 11:3714-21. 2005
    ..In an effort to confirm and expand these observations, we examined CAIX expression in pathology specimens from renal cancer patients who had previously received IL-2 therapy...
  7. ncbi request reprint Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy
    Melissa P Upton
    Beth Israel Deaconess Medical Center, Department of Pathology, Boston, MA 02215, USA
    J Immunother 28:488-95. 2005
    ..Investigation of other tumor-related predictors of IL-2 responsiveness is warranted...
  8. ncbi request reprint Innovations and challenges in melanoma: summary statement from the first Cambridge conference
    Michael B Atkins
    Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Clin Cancer Res 12:2291s-2296s. 2006
    ....
  9. ncbi request reprint Cytokine-based therapy and biochemotherapy for advanced melanoma
    Michael B Atkins
    Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA
    Clin Cancer Res 12:2353s-2358s. 2006
    ....
  10. doi request reprint Treatment selection for patients with metastatic renal cell carcinoma: identification of features favoring upfront IL-2-based immunotherapy
    Michael B Atkins
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center, MASCO Bldg, Rm 412, 375 Longwood Ave, Boston, MA 02215, USA
    Med Oncol 26:18-22. 2009
    ..Taken together, these data offer the possibility to limit the use of this toxic therapy to those most likely to benefit...
  11. pmc Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordin
    Michael B Atkins
    Beth Israel Deaconess Medical Center Dana Farber Cancer Institute, Boston, MA 02215, USA
    J Clin Oncol 26:5748-54. 2008
    ..In an effort to determine the relative efficacy of BCT compared with chemotherapy alone, a phase III trial was performed within the United States Intergroup...
  12. doi request reprint Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group study
    Michael B Atkins
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Cancer 113:2139-45. 2008
    ..The authors tested the efficacy of a regimen including TMZ, thalidomide, and whole brain radiation therapy (WBRT) in patients with brain (CNS) metastases from melanoma...
  13. ncbi request reprint Innovations and challenges in renal cell carcinoma: summary statement from the Second Cambridge Conference
    Michael B Atkins
    Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, USA
    Clin Cancer Res 13:667s-670s. 2007
    ....
  14. pmc Innovations and challenges in renal cancer: summary statement from the Third Cambridge Conference
    Michael B Atkins
    Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    Cancer 115:2247-51. 2009
    ..The conference format combined brief presentations with extended periods of discussion. The conclusions and recommendations are summarized in this paper and presented in more detail in the individual papers that follow...
  15. ncbi request reprint Report on the ISBTC mini-symposium on biologic effects of targeted therapeutics
    Michael B Atkins
    Beth Israel Deaconess Medical Center, Boston, MA, USA
    J Immunother 30:577-90. 2007
    ....
  16. ncbi request reprint Molecular targeted therapy for patients with melanoma: the promise of MAPK pathway inhibition and beyond
    Ryan J Sullivan
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Expert Opin Investig Drugs 19:1205-16. 2010
    ....
  17. ncbi request reprint Management of advanced renal cancer
    Michael B Atkins
    Division of Hematology Oncology, Harvard Medical School, Beth Israel Deaconess Medical Center, and Dana Farber Harvard Cancer Center, Boston, Massachusetts 02215, USA
    Kidney Int 67:2069-82. 2005
  18. pmc Treatment selection for patients with metastatic renal cell carcinoma
    Michael B Atkins
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center, MASCO Bldg, Room 412, 375 Longwood Avenue, Boston, MA 02115, USA
    Cancer 115:2327-33. 2009
    ....
  19. ncbi request reprint Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma
    Michael B Atkins
    Department of Medicine, Division of Hematology Oncology, Beth Israel Deaconess Medical Center, E Campus, Kirstein 158, Boston, MA 02215, USA
    J Clin Oncol 22:909-18. 2004
    ..To evaluate the efficacy, safety, and pharmacokinetics of multiple doses of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma (RCC)...
  20. ncbi request reprint Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinoma
    Michael B Atkins
    Beth Israel Deaconess Medical Center, Dana Farber Cancer Institute, Boston, Massachusetts 02215, USA
    Clin Cancer Res 10:6342S-6S. 2004
    ..Recent efforts have focused on trying to identify factors predictive of response to IL-2 therapy so that this treatment could be limited to those most likely to benefit...
  21. ncbi request reprint Retrospective analysis of the safety and efficacy of interleukin-2 after prior VEGF-targeted therapy in patients with advanced renal cell carcinoma
    Daniel C Cho
    Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    J Immunother 32:181-5. 2009
    ..The assumption that IL-2 therapy can be safely administered after TKI therapy may not be valid. Further examination of the safety of this sequential approach is necessary and more cautious patient selection seems warranted...
  22. doi request reprint Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy
    Toni K Choueiri
    Dana Farber Harvard Cancer Center, Boston, MA, USA
    BJU Int 106:772-8. 2010
    ....
  23. pmc High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinoma
    Xiaoen Wang
    Department of Radiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    J Transl Med 9:220. 2011
    ..However, resistance to therapy develops at a median of 5 months. In an effort to increase efficacy, we studied the effects of increased sorafenib dose and intermittent scheduling in a murine RCC xenograft model...
  24. pmc Resistance of renal cell carcinoma to sorafenib is mediated by potentially reversible gene expression
    Liang Zhang
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America
    PLoS ONE 6:e19144. 2011
    ..We examined whether resistance occurs at least in part via reversible, physiologic changes in the tumor, or results solely from stable genetic changes in resistant tumor cells...
  25. ncbi request reprint Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma
    David F McDermott
    Department of Medicine, Division of Hematology Oncology, Beth Israel Deaconess Medical Center, 330 Brookline Ave, E KS 153, Boston, MA 02215, USA
    J Clin Oncol 23:133-41. 2005
    ..The Cytokine Working Group conducted a randomized phase III trial to determine the value of outpatient interleukin-2 (IL-2) and interferon alfa-2b (IFN) relative to high-dose (HD) IL-2 in patients with metastatic renal cell carcinoma...
  26. ncbi request reprint A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma
    Michael B Atkins
    Department of Medicine, Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    Clin Cancer Res 8:3075-81. 2002
    ....
  27. pmc Does arterial spin-labeling MR imaging-measured tumor perfusion correlate with renal cell cancer response to antiangiogenic therapy in a mouse model?
    Rachel Schor-Bardach
    Minimally Invasive Tumor Therapy Lab, Beth Israel Deaconess Medical Center, Harvard Medical School, 1 Deaconess Rd, WCC 308 B, Boston, MA 02215, USA
    Radiology 251:731-42. 2009
    ..To determine whether arterial spin-labeling (ASL) magnetic resonance (MR) imaging findings at baseline and early during antiangiogenic therapy can predict later resistance to therapy...
  28. doi request reprint Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell ca
    Katherine M Krajewski
    Department of Imaging, Dana Farber Cancer Institute, Boston, MA, USA
    Eur Urol 59:856-62. 2011
    ..Since these therapies can induce tumor necrosis and minimal tumor shrinkage, Response Evaluation Criteria in Solid Tumors (RECIST) may not be optimal for predicting clinical outcome...
  29. pmc A phase 2 pilot trial of low-dose, continuous infusion, or "metronomic" paclitaxel and oral celecoxib in patients with metastatic melanoma
    Rupal S Bhatt
    Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    Cancer 116:1751-6. 2010
    ..Angiogenesis, which is the growth of new blood vessels, is necessary for tumor growth and progression. Thus, the authors tested the safety and efficacy of a low dose of paclitaxel and celecoxib in patients with MM...
  30. ncbi request reprint A phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: a Cytokine Working Group (CWG) study
    Uday B Dandamudi
    Dartmouth Hitchcock Medical Center, Lebanon, NH Dana Farber Cancer Institute, Harvard School of Public Health Beth Israel Deaconess Medical Center Dana Farber Cancer Institute, Harvard Medical School, Boston, MA Vanderbilt University Medical Center, Nashville, TN Loyola University Medical Center, Maywood, IL Georgetown Lombardi Comprehensive Cancer Center, Washington, DC St Luke s Roosevelt Hospital Center, New York, NY Earle A Chiles Research Institute Providence Cancer Center, Portland, OR Department of Oncology, Wayne State University, Karmanos Cancer Institute, Detroit, MI Division of Oncology, Department of Medicine, University of Washington, Seattle Cancer Care Alliance, Seattle, WA
    J Immunother 36:490-5. 2013
    ..Combining IL-2 plus bevacizumab is feasible, with a response rate and PFS at least as high as reported previously for the single agents. The regimen did not appear to enhance the rate of durable major responses over that of IL-2 alone. ..
  31. pmc The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma
    Daniel C Cho
    Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Clin Cancer Res 16:3628-38. 2010
    ....
  32. ncbi request reprint Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma
    Jared A Gollob
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    J Clin Oncol 21:2564-73. 2003
    ....
  33. ncbi request reprint Combination of radiofrequency ablation with antiangiogenic therapy for tumor ablation efficacy: study in mice
    Antoine Hakime
    Laboratory for Minimally Invasive Tumor Therapy, Department of Radiology, Beth Israel Deaconess Medical Center, 1 Deaconess Rd, WCC 308B, Boston, MA 02215, USA
    Radiology 244:464-70. 2007
    ..To prospectively determine whether modulation of renal cell carcinoma (RCC) tumor microvasculature by using the antiangiogenic drug sorafenib could increase the extent of radiofrequency (RF)-induced coagulation in an RCC animal tumor model...
  34. ncbi request reprint Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma
    David E Avigan
    Beth Israel Deaconess Medical Center and Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA
    J Immunother 30:749-61. 2007
    ..Vaccination of patients with RCC with allogeneic DC/tumor fusions was feasible, well tolerated, and resulted in immunologic and clinical responses in a subset of patients...
  35. ncbi request reprint The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer
    Daniel Cho
    Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, USA
    Clin Cancer Res 13:758s-763s. 2007
    ..With an increasing number of active agents for treatment of patients with RCC, efforts must continue to develop patient selection models based on predictive biomarkers to direct therapy to appropriate patients...
  36. pmc Renal cancer resistance to antiangiogenic therapy is delayed by restoration of angiostatic signaling
    Rupal S Bhatt
    Division of Hematology Oncology and Cancer Biology, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Mol Cancer Ther 9:2793-802. 2010
    ....
  37. ncbi request reprint Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors
    Allison Ackerman
    Department of Medicine, Division of Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts
    Cancer 120:1695-701. 2014
    ..This retrospective analysis describes the outcomes of patients treated with either BRAFi before IT or IT before BRAFi...
  38. ncbi request reprint Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma
    Keith T Flaherty
    Massachusetts General Hospital, 55 Fruit St, Yawkey 9E, Boston, MA 02114, USA
    J Clin Oncol 31:373-9. 2013
    ..The primary objective of this study was to determine whether carboplatin, paclitaxel, and sorafenib (CPS) improve overall survival (OS) compared with carboplatin and paclitaxel (CP) in chemotherapy-naive patients with metastatic melanoma...
  39. pmc Rapid development of hypertension by sorafenib: toxicity or target?
    Benjamin D Humphreys
    Renal Division, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Clin Cancer Res 15:5947-9. 2009
    ..Blood pressure rises on the first day of treatment, facilitating design and interpretation of future trials aiming to correlate blood pressure changes with clinical outcomes...
  40. ncbi request reprint Perfusion MDCT enables early detection of therapeutic response to antiangiogenic therapy
    Adeel Sabir
    Minimally Invasive Tumor Therapy Laboratory, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
    AJR Am J Roentgenol 191:133-9. 2008
    ..The objective of our study was to determine whether perfusion CT can be used to detect early changes in therapeutic response to antiangiogenic therapy in an animal tumor model...
  41. doi request reprint Predictors of response to sequential sunitinib and the impact of prior VEGF-targeted drug washout in patients with metastatic clear-cell renal cell carcinoma
    Aymen A Elfiky
    Dana Farber Harvard Cancer Center, Harvard Medical School, Boston, MA 02115, USA
    Urol Oncol 29:756-63. 2011
    ..To identify factors that can be used to identify metastatic clear cell RCC patients more likely to benefit from sequential sunitinib...
  42. pmc Utility of 3-year torso computed tomography and head imaging in asymptomatic patients with high-risk melanoma
    Erin R Derose
    The Cutaneous Oncology Program, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    Melanoma Res 21:364-9. 2011
    ..Furthermore, given the low risk of recurrence beyond 3 years, it is likely that subsequent routine imaging would have similarly low utility...
  43. doi request reprint Impact of concomitant immunosuppression on the presentation and prognosis of patients with melanoma
    Amy Frankenthaler
    Cutaneous Oncology Program, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Melanoma Res 20:496-500. 2010
    ..The additional observation that the stage-specific recurrence rates were similar, however, suggests that routine dermatologic screening of immunosuppressed patients may lead to earlier diagnosis and improved outcomes...
  44. ncbi request reprint GSK-3beta inhibition enhances sorafenib-induced apoptosis in melanoma cell lines
    David J Panka
    Division of Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    J Biol Chem 283:726-32. 2008
    ..These data provide a strong rationale for the use of GSK-3beta inhibitors as adjuncts to sorafenib treatment and suggest that preservation of Noxa may contribute to their efficacy...
  45. doi request reprint Arterial spin labeling MR imaging for characterisation of renal masses in patients with impaired renal function: initial experience
    Ivan Pedrosa
    Department of Radiology, Beth Israel Deaconess Medical Center and Harvard Medical School, 330 Brookline Ave, Boston, MA 02215, USA
    Eur Radiol 22:484-92. 2012
    ..To retrospectively evaluate the feasibility of arterial spin labeling (ASL) magnetic resonance imaging (MRI) for the assessment of vascularity of renal masses in patients with impaired renal function...
  46. doi request reprint Results of a multicenter, randomized, double-blind, dose-evaluating phase 2/3 study of lenalidomide in the treatment of metastatic malignant melanoma
    John Glaspy
    Department of Medicine, UCLA Medical Center, Los Angeles, CA 90095, USA
    Cancer 115:5228-36. 2009
    ....
  47. doi request reprint Immunotherapy of metastatic renal cell carcinoma
    David F McDermott
    Beth Israel Deaconess Medical Center, Department of Medicine, Harvard Medical School, and Dana Farber Harvard Cancer Center Renal Cancer Program, Boston, MA 02215, USA
    Cancer J 14:320-4. 2008
    ..As the list of effective therapies for metastatic RCC grows, improvements in patient selection and more "targeted" approaches will be required to optimize the benefits of cytokine therapy in metastatic RCC...
  48. ncbi request reprint Interleukin-2 therapy of metastatic renal cell carcinoma: update of phase III trials
    David F McDermott
    Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Clin Genitourin Cancer 5:114-9. 2006
    ..This year, investigators will launch a clinical trial designed to prospectively determine whether patients who are more likely to respond to high-dose IL-2 can be identified before therapy is initiated...
  49. ncbi request reprint The effect of recent drug approvals on translational research and drug development
    Michael B Atkins
    Beth Israel Deaconess Medical Center, Dana Farber Harvard Cancer Center, and Harvard Medical School, Boston, MA 02215, USA
    Clin Adv Hematol Oncol 5:285-7. 2007
  50. ncbi request reprint Opportunities and obstacles to combination targeted therapy in renal cell cancer
    Jeffrey A Sosman
    Vanderbilt Ingram Cancer Center, Division of Hematology Oncology, Vanderbilt University Medical Center, Nashville, TN 37232, USA
    Clin Cancer Res 13:764s-769s. 2007
    ..Many of the above strategies are ongoing and will require careful phase 1 determination of toxicity and even more rigorous phase 2 analysis before moving onto phase 3 trials...
  51. ncbi request reprint Update on therapy for melanoma: opportunities for patient selection and overcoming tumor resistance
    Henry B Koon
    Beth Israel Deaconess Medical Center, Biologic Therapeutics Program, 330 Brookline Avenue, Boston, Massachusetts 02215, USA
    Expert Rev Anticancer Ther 7:79-88. 2007
    ..These strategies hold the promise of extending the clinical benefits of current therapies as well as facilitating the development of additional and more active treatments...
  52. ncbi request reprint Interleukin-2 therapy of metastatic renal cell carcinoma--predictors of response
    David F McDermott
    Beth Israel Deaconess Medical Center and the Dana Farber Harvard Cancer Center Renal Cancer Program, Boston, MA 02215, USA
    Semin Oncol 33:583-7. 2006
    ..This year, investigators will launch a clinical trial designed to prospectively determine if patients who are more likely to respond to high-dose IL-2 can be identified prior to starting therapy...
  53. pmc Future directions in renal cell carcinoma: 2011 and beyond
    Daniel C Cho
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USA
    Hematol Oncol Clin North Am 25:917-35. 2011
    ..This review discusses challenges that face physicians and researchers as well as innovations that may contribute to improving the therapeutic outcomes for patients with RCC...
  54. ncbi request reprint Application of IL-2 and other cytokines in renal cancer
    David F McDermott
    Beth Israel Deaconess Medical Center, Boston, MA 02186, USA
    Expert Opin Biol Ther 4:455-68. 2004
    ....
  55. ncbi request reprint Innovations and challenges in renal cancer: consensus statement from the first international conference
    Michael B Atkins
    Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Clin Cancer Res 10:6277S-81S. 2004
  56. ncbi request reprint Exploiting regulatory T-cell populations for the immunotherapy of cancer
    Hans J J van der Vliet
    Cancer Biology Program, Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    J Immunother 30:591-5. 2007
    ..Therapeutic modulation of these regulatory T-cell populations is clinically feasible and will potentially allow the induction of effective antitumor immune responses when combined with currently available immunotherapeutic strategies...
  57. pmc Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study
    Fabio A B Schutz
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Lancet Oncol 14:81-7. 2013
    ..Germline genetic polymorphisms might affect the risk of recurrence in patients with localised renal-cell carcinoma. We investigated the association between genetic polymorphisms and recurrence of renal-cell carcinoma...
  58. doi request reprint BRAF mutations in metanephric adenoma of the kidney
    Toni K Choueiri
    Dana Farber Cancer Institute, Boston, MA 02215, USA
    Eur Urol 62:917-22. 2012
    ..Metanephric adenoma (MA) of the kidney is a rare, indolent tumor that may be difficult to differentiate from other small renal masses (SRMs). Genetic alterations associated with MA remain largely unknown...
  59. doi request reprint Phase II trial of carboplatin and paclitaxel in papillary renal cell carcinoma
    Kathryn A Bylow
    Department of Medicine, Section of Hematology Oncology, University of Chicago, IL, USA
    Clin Genitourin Cancer 7:39-42. 2009
    ..Cytotoxic chemotherapy has not been well investigated in non-clear-cell renal cell carcinoma (RCC). A phase II study was thus conducted to assess the efficacy of carboplatin and paclitaxel in such patients...
  60. ncbi request reprint Targeting the mitogen-activated protein kinase pathway in the treatment of malignant melanoma
    David J Panka
    Division of Oncology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA
    Clin Cancer Res 12:2371s-2375s. 2006
    ....
  61. ncbi request reprint Targeted therapies: sunitinib in RCC-expanded access equals expanded benefit?
    Toni K Choueiri
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    Nat Rev Clin Oncol 6:679-80. 2009
    ..in an expanded-access study, sunitinib has demonstrated clinical benefit with an acceptable safety profile in a population of patients that is representative of those seen in clinical practice...
  62. ncbi request reprint Emerging clinical issues in melanoma in the molecularly targeted era
    Ryan J Sullivan
    Center for Melanoma, Massachusetts General Hospital Cancer Center, Boston, MA, USA
    Methods Mol Biol 1102:11-26. 2014
    ..In this chapter, five critical, emerging clinical issues are presented with descriptions of approaches that might be expected to help solve these challenges to optimal patient care...
  63. ncbi request reprint Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab
    Suzanne L Topalian
    Suzanne L Topalian, William H Sharfman, Julie R Brahmer, Evan J Lipson, Janis M Taube, and Drew M Pardoll, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD Mario Sznol and Harriet M Kluger, Yale University School of Medicine and Smilow Cancer Center, Yale New Haven Hospital, New Haven, CT David F McDermott, Beth Israel Deaconess Medical Center Donald P Lawrence, Massachusetts General Hospital Cancer Center F Stephen Hodi, Dana Farber Cancer Institute, Boston, MA Richard D Carvajal, Memorial Sloan Kettering Cancer Center, New York, NY Michael B Atkins, Georgetown Lombardi Comprehensive Cancer Center, Washington, DC John D Powderly, Carolina BioOncology Institute, Huntersville, NC Philip D Leming, The Christ Hospital Cancer Center, Cincinnati, OH Igor Puzanov and Jeffrey A Sosman, Vanderbilt University Medical Center, Nashville, TN David C Smith, University of Michigan, Ann Arbor, MI and Jon M Wigginton, Georgia D Kollia, and Ashok Gupta, School of Medical Sciences
    J Clin Oncol 32:1020-30. 2014
    ..PD-1 blockade can mediate tumor regression in a substantial proportion of patients with melanoma, but it is not known whether this is associated with extended survival or maintenance of response after treatment is discontinued...
  64. doi request reprint Immune therapy for kidney cancer: a second dawn?
    David F McDermott
    Biologic Therapy Program, Beth Israel Deaconess Medical Center Department of Medicine, Harvard Medical School, Boston, MA, USA
    Semin Oncol 40:492-8. 2013
    ..Novel approaches including inhibition of immune checkpoints has entered clinical testing in RCC. ..
  65. ncbi request reprint Interleukin-2: clinical applications
    Michael B Atkins
    Cutaneous Oncology and Biologic Therapy Programs, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Semin Oncol 29:12-7. 2002
    ..It remains to be determined whether further modifications of IL-2-based regimens or the addition of newer agents to IL-2 will produce better tumor response and survival...
  66. ncbi request reprint Effects of the administration of high-dose interleukin-2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancer
    Hans J van der Vliet
    Cancer Biology Program, Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02115, USA
    Clin Cancer Res 13:2100-8. 2007
    ..Although IL-2 is well known as a T-cell growth factor, its potential in vivo effects on human immunoregulatory cell subsets are largely unexplored...
  67. ncbi request reprint Systemic therapy for renal cell carcinoma
    Yoo Joung Ko
    Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Cancer Chemother Biol Response Modif 22:263-72. 2005
  68. ncbi request reprint Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy
    Ken Wyman
    Division of Hematology Oncology, Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee 37232, USA
    Cancer 106:2005-11. 2006
    ..Signal transduction via c-kit, PDGFR-alpha, and PDGFR-beta has been demonstrated in malignant melanoma...
  69. doi request reprint Which drug, and when, for patients with BRAF-mutant melanoma?
    Sekwon Jang
    Department of Medicine, Georgetown University School of Medicine, Washington, DC, USA
    Lancet Oncol 14:e60-9. 2013
    ..We review the available data to best guide initial treatment choice and the sequence of treatments for patients with BRAF Val600 mutant melanoma...
  70. ncbi request reprint Serum cholesterol and mTOR inhibitors: surrogate biomarker or epiphenomenon?
    Daniel C Cho
    Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Clin Cancer Res 18:2999-3001. 2012
    ..Although these findings must be validated prospectively, it should also be determined if this marker is a true mechanism-based toxicity or an epiphenomenon associated with therapy...
  71. pmc Tissue-based research in kidney cancer: current challenges and future directions
    Sabina Signoretti
    Department of Pathology, Brigham and Women s Hospital and Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    Clin Cancer Res 14:3699-705. 2008
    ..In addition, some practical implementation strategies are proposed. Although many of the topics discussed are specific for renal cancer, several are also relevant to tissue based biomarker investigations in a broad array of malignancies...
  72. ncbi request reprint Renal cell carcinoma: dynamic contrast-enhanced MR imaging for differentiation of tumor subtypes--correlation with pathologic findings
    Maryellen R M Sun
    Department of Radiology, Beth Israel Deaconess Medical Center, 330 Brookline Ave, Boston, MA 02215, USA
    Radiology 250:793-802. 2009
    ....
  73. ncbi request reprint Induction of myasthenia gravis, myositis, and insulin-dependent diabetes mellitus by high-dose interleukin-2 in a patient with renal cell cancer
    Paula G Fraenkel
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    J Immunother 25:373-8. 2002
    ..This case demonstrates the importance of prompt recognition of IL-2-induced MG and shows how this complication can be successfully managed with aggressive therapy...
  74. ncbi request reprint The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells
    David J Panka
    Division of Oncology, Beth Israel Deaconess Medical Center and Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USA
    Cancer Res 66:1611-9. 2006
    ..These data indicate that in sensitive cell lines, BAY 43-9006-induced apoptosis is independent of Bad dephosphorylation and caspase activation and largely mediated through the nuclear translocation of AIF...
  75. pmc Prospective evaluation of analgesic use and risk of renal cell cancer
    Eunyoung Cho
    Channing Laboratory, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Arch Intern Med 171:1487-93. 2011
    ..Epidemiologic data suggest that analgesic use increases the risk of renal cell cancer (RCC), but few prospective studies have been published. We investigated the association between analgesic use and RCC in 2 large prospective studies...
  76. doi request reprint Molecular-targeted therapy in malignant melanoma
    Ryan J Sullivan
    Beth Israel Deaconess Medical Center, Harvard Medical School, Division of Hematology Oncology, Boston, MA, USA
    Expert Rev Anticancer Ther 9:567-81. 2009
    ..This article presents a review of the limitations of current therapy, a description of key pathogenic mechanisms for which inhibitors exist and a summary of therapeutic trials of molecularly targeted agents in this disease...
  77. pmc Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma
    Richard W Joseph
    Department of Melanoma Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Immunother 35:66-72. 2012
    ..56 vs. 1.97 y, P<0.0001), and trended toward a decreased response rate (7% vs. 21%, P=0.08). NRAS mutational status is a new candidate biomarkers for selecting patients with melanoma for HD IL-2 treatment...
  78. ncbi request reprint Treatment of patients with metastatic renal cell cancer: a RAND Appropriateness Panel
    Ronald J Halbert
    Cerner Life Sciences, Beverley Hills, California, USA
    Cancer 107:2375-83. 2006
    ..The authors convened a panel of medical and urologic oncologists to rate the appropriateness of the main options...
  79. ncbi request reprint Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma
    Malcolm S Mitchell
    University of California, San Diego, School of Medicine and Cancer Center, San Diego, CA, USA
    J Clin Oncol 25:2078-85. 2007
    ..To compare the overall survival (OS) of patients with resected stage III melanoma administered active specific immunotherapy and low-dose interferon alfa-2b (IFN-alpha-2b) with the OS achieved using high-dose IFN-alpha-2b...
  80. ncbi request reprint Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial
    Joseph I Clark
    Cardinal Bernardin Cancer Center, Loyola University Medical Center, 2160 South First Avenue, Maywood, IL 60153, USA
    J Clin Oncol 21:3133-40. 2003
    ..This prospective, randomized, controlled phase III trial assessed high-dose bolus interleukin-2 (IL-2) postoperatively in patients with high-risk renal cell carcinoma (RCC)...
  81. ncbi request reprint New TNM melanoma staging system: linking biology and natural history to clinical outcomes
    Charles M Balch
    Johns Hopkins Medical Institutions, Baltimore, MD, USA
    Semin Surg Oncol 21:43-52. 2003
    ....
  82. pmc Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma
    Jeffrey A Sosman
    Vanderbilt Ingram Cancer Center Vanderbilt, University Medical Center, Section of Hematology Oncology, 777 Preston Research Bldg, Nashville, TN 37232 6307, USA
    J Clin Oncol 26:2292-8. 2008
    ..We evaluated 210M with one of three different IL-2 schedules to determine whether a basis exists for a phase III trial...
  83. ncbi request reprint An evidence-based staging system for cutaneous melanoma
    Charles M Balch
    American Society of Clinical Oncology, Alexandria, VA, USA
    CA Cancer J Clin 54:131-49; quiz 182-4. 2004
    ..6) A new convention was implemented for defining clinical and pathological staging so as to take into account the new staging information gained from lymphatic mapping and sentinel node biopsy...
  84. ncbi request reprint Chemotherapies and immunotherapies for metastatic kidney cancer
    Yoo Joung Ko
    Division of Medical Oncology Hematology, Sunnybrook and Women s College Health Sciences Centre, 2075 Bayview Avenue, T Wing, Toronto, Ontario, Canada
    Curr Urol Rep 6:35-42. 2005
    ..Novel agents targeting the vascular endothelial growth factor, its receptor, and other hypoxia-induced proteins are showing great promise and soon may expand the therapeutic options for patients with advanced kidney cancer...
  85. ncbi request reprint Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion
    Arnold H Zea
    Stanley S Scott Cancer Center, Department of Immunology and Microbiology, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA
    Cancer Res 65:3044-8. 2005
    ..In addition, it supports the concept that blocking arginase may be an important step in the success of immunotherapy...
  86. doi request reprint Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials
    Edward L Korn
    Biometric Research Branch, EPN 8129, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA
    J Clin Oncol 26:527-34. 2008
    ....
  87. ncbi request reprint Phase I/II trial of outpatient PEG-interferon with interleukin-2 in advanced renal cell carcinoma: a cytokine working group study
    Joseph I Clark
    Cardinal Bernardin Cancer Center, Loyola University Chicago, Maywood, IL 60153, USA
    J Immunother 30:839-46. 2007
    ..Despite clinical efficacy, the study was closed prematurely owing to excess toxicity. Although all serious adverse events resolved, this degree of toxicity is unacceptable for an outpatient treatment regimen...
  88. doi request reprint Melanoma complicating treatment with natalizumab for multiple sclerosis
    John T Mullen
    N Engl J Med 358:647-8. 2008
  89. ncbi request reprint More support for the judicious use of high-dose interleukin-2 in patients with advanced melanoma
    David F McDermott
    J Clin Oncol 25:3791-3. 2007
  90. ncbi request reprint Phase I trial of BAY 50-4798, an interleukin-2-specific agonist in advanced melanoma and renal cancer
    Kim Margolin
    City of Hope National Medical Center, Duarte, California 91010 3000, USA
    Clin Cancer Res 13:3312-9. 2007
    ..This phase I study was designed to determine the maximum tolerated dose (MTD) and safety of BAY 50-4798, screen for tumor response, and assess pharmacokinetics...
  91. ncbi request reprint Management of cutaneous melanoma
    Hensin Tsao
    Department of Dermatology, Massachusetts General Hospital Melanoma Center, Massachusetts General Hospital and Harvard Medical School, Boston 02114, USA
    N Engl J Med 351:998-1012. 2004
  92. ncbi request reprint Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy
    Ulrich Keilholz
    UKBF Free University, Berlin, Germany
    J Immunother 25:97-138. 2002
    ..At present, assays appear to be most useful as measures of vaccine potency. Careful immune monitoring in association with larger scale clinical trials ultimately may enable the correlation of monitoring results with clinical benefit...
  93. ncbi request reprint 18th Annual Scientific Meeting of the International Society for Biological Therapy of Cancer. 30 October-2 November 2003, Bethesda, Maryland, USA
    Francesco M Marincola
    Immunogenetics Section, Department of Transfusion Medicine, Clinical Center, NIH, Bldg 10, R 1C711, 9000 Rockville Pike, Bethesda, MD 20892, USA
    Expert Opin Biol Ther 4:107-14. 2004
    ..The President of the Society is Dr Michael B Atkins from Beth Israel Deaconess Medical Center, Boston, MA and the Vice President is Ulrich Keilholz from UKBF, ..